Get all premium features to the best stock analysis tool

Finranks

Finranks

Company

  • About us

Contact us

  • [email protected]

Follow us

  • Instagram
  • Telegram
  • LinkedIn

All rights reserved.

Privacy PolicyTerms of Conditions
  • Home
  • Markets
  • Screener
  • News
  • About
  1. Home
  2. BNGO
B

Bionano Genomics, Inc. (BNGO)

NCM – Real Time Price. Currency in USD

1.16

+0.01 (0.87%)

At close: Mar 27, 2026, 4:00 PM EDT

1.14

-0.02 (-1.72%)

After-hours: Mar 27, 2026, 7:44 PM EDT

  • Summary
  • News
  • Chart
  • Financial
  • Dividends
  • Forecast
  • Ownership
  • Profile
Bionano Genomics, Inc. (BNGO) Q4 2025 Earnings Call Transcript
23.03.2026

Bionano Genomics, Inc. (BNGO) Q4 2025 Earnings Call Transcript

Bionano Genomics, Inc. (BNGO) Q4 2025 Earnings Call Transcript

Bionano Genomics Stock Soars As Efficiency Gains Meet Growth Story
23.03.2026

Bionano Genomics Stock Soars As Efficiency Gains Meet Growth Story

Despite a slight year-over-year revenue dip, the stock showed resilience, gaining nearly 27% in Monday's regular session.

Bionano Reports Fourth Quarter and Full-Year 2025 Results and Provides Revenue Outlook for 2026
23.03.2026

Bionano Reports Fourth Quarter and Full-Year 2025 Results and Provides Revenue Outlook for 2026

SAN DIEGO, March 23, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the fourth quarter and full year ended December 31, 2025. "2025 demonstrated the momentum we built as a business,” commented Erik Holmlin, PhD, president and CEO of Bionano.

Bionano Genomics Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
20.03.2026

Bionano Genomics Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Bionano Genomics, Inc. (NASDAQ: BNGO) will release earnings results for its fourth quarter, after the closing bell on Monday, March 23.

Bionano to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call Webcast on March 23, 2026
09.03.2026

Bionano to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call Webcast on March 23, 2026

SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Monday, March 23, 2026, at 4:30 p.m. Eastern Time to report financial results for the fourth quarter and full year 2025 and to highlight recent corporate progress.

Bionano Symposium 2026 Concluded with 9 Speakers Describing the Breadth of Bionano Solutions and Their Potential for Use on a Large Scale
27.02.2026

Bionano Symposium 2026 Concluded with 9 Speakers Describing the Breadth of Bionano Solutions and Their Potential for Use on a Large Scale

SAN DIEGO, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced highlights from the fourth and final day of Symposium 2026. Day 4 featured updates from some of the most advanced and high-volume cytogenetics and molecular pathology laboratories in the United States, Canada and Europe describing how they envision scaling optical genome mapping (OGM), including processing up to thousands of samples per year with automation, multiple OGM systems, and VIA™ software. Other talks covered topics like Bionano's Ionic® system for isolating DNA and RNA for next generation sequencing (NGS) and advanced analytical tools that could be the future of digital cytogenetics and molecular pathology by enabling digital karyotype construction.

10 Presentations on Day 3 of Bionano Symposium 2026 Showcase OGM's Utility in Unraveling the Complex Puzzles of Constitutional Genetic Disorders
26.02.2026

10 Presentations on Day 3 of Bionano Symposium 2026 Showcase OGM's Utility in Unraveling the Complex Puzzles of Constitutional Genetic Disorders

SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced highlights from Day 3 of Bionano Symposium 2026, entitled OGM Making its Mark in Constitutional Genetic Disorders. Presentations highlighted how these conditions, which include developmental delay, intellectual disability, neuromuscular disorders, reproductive disorders, birth defects and other so-called rare diseases, present unique challenges to the cytogenetics and molecular pathology teams investigating them. Unlike hematologic malignancies, where established guidelines may better define the search for relevant chromosomal aberrations and genetic variants, the genetic drivers of constitutional disorders are more typically unknown, which makes Bionano's end-to-end workflow based on the unbiased, genome-wide approach of optical genome mapping (OGM) particularly useful. Attendance at Symposium 2026 has grown to more than 1,200 participants from over 73 countries, with Day 3's presentations coming from Japan, India, Brazil, the Netherlands, Turkey, and the United States, while the online poster hall now features 50 posters.

Videos

No Data

There is no data to display

Press releases

Bionano Reports Fourth Quarter and Full-Year 2025 Results and Provides Revenue Outlook for 2026
23.03.2026

Bionano Reports Fourth Quarter and Full-Year 2025 Results and Provides Revenue Outlook for 2026

SAN DIEGO, March 23, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the fourth quarter and full year ended December 31, 2025. "2025 demonstrated the momentum we built as a business,” commented Erik Holmlin, PhD, president and CEO of Bionano.

Bionano Symposium 2026 Concluded with 9 Speakers Describing the Breadth of Bionano Solutions and Their Potential for Use on a Large Scale
27.02.2026

Bionano Symposium 2026 Concluded with 9 Speakers Describing the Breadth of Bionano Solutions and Their Potential for Use on a Large Scale

SAN DIEGO, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced highlights from the fourth and final day of Symposium 2026. Day 4 featured updates from some of the most advanced and high-volume cytogenetics and molecular pathology laboratories in the United States, Canada and Europe describing how they envision scaling optical genome mapping (OGM), including processing up to thousands of samples per year with automation, multiple OGM systems, and VIA™ software. Other talks covered topics like Bionano's Ionic® system for isolating DNA and RNA for next generation sequencing (NGS) and advanced analytical tools that could be the future of digital cytogenetics and molecular pathology by enabling digital karyotype construction.

10 Presentations on Day 3 of Bionano Symposium 2026 Showcase OGM's Utility in Unraveling the Complex Puzzles of Constitutional Genetic Disorders
26.02.2026

10 Presentations on Day 3 of Bionano Symposium 2026 Showcase OGM's Utility in Unraveling the Complex Puzzles of Constitutional Genetic Disorders

SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced highlights from Day 3 of Bionano Symposium 2026, entitled OGM Making its Mark in Constitutional Genetic Disorders. Presentations highlighted how these conditions, which include developmental delay, intellectual disability, neuromuscular disorders, reproductive disorders, birth defects and other so-called rare diseases, present unique challenges to the cytogenetics and molecular pathology teams investigating them. Unlike hematologic malignancies, where established guidelines may better define the search for relevant chromosomal aberrations and genetic variants, the genetic drivers of constitutional disorders are more typically unknown, which makes Bionano's end-to-end workflow based on the unbiased, genome-wide approach of optical genome mapping (OGM) particularly useful. Attendance at Symposium 2026 has grown to more than 1,200 participants from over 73 countries, with Day 3's presentations coming from Japan, India, Brazil, the Netherlands, Turkey, and the United States, while the online poster hall now features 50 posters.

11 Presentations on Day 2 of Bionano Symposium 2026 Showcase Expanding Impact of Optical Genome Mapping Across Oncology and Cell & Gene Therapy
25.02.2026

11 Presentations on Day 2 of Bionano Symposium 2026 Showcase Expanding Impact of Optical Genome Mapping Across Oncology and Cell & Gene Therapy

SAN DIEGO, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced highlights from Day 2 of Bionano Symposium 2026, which focused on New Frontiers in Oncology and Bioprocessing Applications with Optical Genome Mapping (OGM). The session revealed how OGM can offer a new standard for detecting and characterizing structural variants (SVs) across cancer, including its unprecedented resolution in rare and heterogeneous cancers.